Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

VICTORIA, British Columbia--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it
will be featured as a presenting company at the H. C. Wainwright Annual
Global Life Sciences Conference. The conference is being held on April
8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

Richard Glickman, Aurinia’s Chief Executive Officer, will provide a
corporate overview during the live presentation and will be available to
participate in one-on-one meetings with investors who are registered to
attend the conference.

If you are an institutional investor, and would like to attend the
presentation, please click on the following link (www.hcwevents.com
) to register for the conference. Once your registration is confirmed,
you will be prompted to log into the conference website to request a
one-on-one meeting.

The presentation will be webcast live. To access the webcast, please
visit www.hcwevents.com.
A replay will remain available for 90 days following the live
presentation.

About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS, and DES. The company is headquartered in
Victoria, BC and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.